Cytokinetics, Incorporated
CYTK
$64.66
$1.151.81%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 87.21M | 85.74M | 19.22M | 18.47M | 3.22M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 87.21M | 85.74M | 19.22M | 18.47M | 3.22M |
| Cost of Revenue | 405.26M | 390.64M | 357.68M | 339.41M | 330.76M |
| Gross Profit | -318.05M | -304.90M | -338.46M | -320.93M | -327.54M |
| SG&A Expenses | 254.89M | 242.08M | 227.18M | 215.31M | 197.09M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 660.14M | 632.72M | 584.86M | 554.72M | 527.85M |
| Operating Income | -572.93M | -546.98M | -565.64M | -536.25M | -524.63M |
| Income Before Tax | -751.94M | -606.31M | -615.26M | -589.53M | -576.40M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -751.94 | -606.31 | -615.26 | -589.53 | -576.40 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -751.94M | -606.31M | -615.26M | -589.53M | -576.40M |
| EBIT | -572.93M | -546.98M | -565.64M | -536.25M | -524.63M |
| EBITDA | -563.29M | -537.60M | -556.14M | -526.72M | -511.14M |
| EPS Basic | -6.31 | -5.12 | -5.31 | -5.28 | -5.39 |
| Normalized Basic EPS | -3.94 | -3.20 | -3.32 | -3.30 | -3.37 |
| EPS Diluted | -6.31 | -5.12 | -5.31 | -5.28 | -5.39 |
| Normalized Diluted EPS | -3.94 | -3.20 | -3.32 | -3.30 | -3.37 |
| Average Basic Shares Outstanding | 476.01M | 473.71M | 463.50M | 446.92M | 427.92M |
| Average Diluted Shares Outstanding | 476.01M | 473.71M | 463.50M | 446.92M | 427.92M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |